Datapoint: Fotivda Scores Kidney Cancer Nod

The FDA last week approved Aveo Oncology’s Fotivda as a third-line treatment for kidney cancer, following years of regulatory hurdles. Pfizer’s Sutent is one of the most advantaged drugs in the kidney cancer space, holding preferred formulary placement for 20% of covered lives, growing to 52% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 3/17/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 26

Datapoint: J&J Sees Potential Stelara Rival in Alvotech-Teva Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 25

Datapoint: Ohio Counties Offer the Most Medicare Advantage Plans

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 24

Datapoint: Dupixent Scores First-in-Class EoE Nod

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today